NIASPAN TABLET (EXTENDED-RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
23-10-2015
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
NICOTINIC ACID
Tillgänglig från:
SUNOVION PHARMACEUTICALS CANADA INC
ATC-kod:
C10AD02
INN (International namn):
NICOTINIC ACID
Dos:
1000MG
Läkemedelsform:
TABLET (EXTENDED-RELEASE)
Sammansättning:
NICOTINIC ACID 1000MG
Administreringssätt:
ORAL
Enheter i paketet:
30
Receptbelagda typ:
Prescription
Terapiområde:
MISCELLANEOUS ANTILIPEMIC AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108396010; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2017-06-30
Produktens egenskaper
PRODUCT MONOGRAPH
PR
NIASPAN
®
Extended-Release Niacin
500 mg and 1000 mg Extended-Release Tablets
Lipid Metabolism Regulator
Manufacturer:
DATE OF REVISION:
Sunovion Pharmaceuticals Canada Inc.
October 23, 2015
6790 Century Ave. Suite 100
Mississauga, Ontario
Canada
Submission #: 185768
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
7
DRUG INTERACTIONS
..........................................................................................................
11
DOSAGE AND ADMINISTRATION
......................................................................................
12
OVERDOSAGE
........................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
14
STORAGE AND STABILITY
.................................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 16
PART II: SCIENTIFIC INFORMATION
..............................................................................
17
PHARMACEUTICAL INFORMATION
.................................................................................
17
CLINICAL
TRIALS...............................................................................................
Läs hela dokumentet
